Jump to content

MRNA-1283: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
 
(18 intermediate revisions by 13 users not shown)
Line 1: Line 1:
{{cs1 config|name-list-style=vanc}}
{{Lowercase title}}
{{short description|Vaccine candidate against COVID-19}}
{{short description|Vaccine candidate against COVID-19}}
{{Use dmy dates|date=December 2021}}
{{Use dmy dates|date=December 2021}}
Line 4: Line 6:
| Verifiedfields =
| Verifiedfields =
| verifiedrevid =
| verifiedrevid =
| drug_name =
| drug_name = mRNA-1283
| INN =
| INN =
| type = vaccine
| type = vaccine
| image =
| image =
| alt =
| alt =
| caption =
| caption =
| target = [[Severe acute respiratory syndrome coronavirus 2|SARS-CoV-2]]
| target = [[Severe acute respiratory syndrome coronavirus 2|SARS-CoV-2]]
| vaccine_type = mrna
| vaccine_type = mrna
<!-- Clinical data -->
<!-- Clinical data -->
| pronounce =
| pronounce =
| tradename = Spikevax<ref>{{cite news |title=Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day |url=https://www.bloomberg.com/press-releases/2021-09-09/moderna-announces-significant-advances-across-industry-leading-mrna-portfolio-at-2021-r-d-day |access-date=29 April 2022 |agency=Bloomberg |date=9 September 2021}}</ref>
| tradename =
| Drugs.com =
| Drugs.com =
| MedlinePlus =
| MedlinePlus =
Line 42: Line 44:
}}
}}
{{COVID-19 pandemic sidebar}}
{{COVID-19 pandemic sidebar}}
'''mRNA-1283''' is a [[COVID-19 vaccine]] candidate developed by [[Moderna]].<ref>{{#invoke:Cite web| |title=A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04813796 |website=[[ClinicalTrials.gov]] |date=24 March 2021 |id=NCT04813796 |access-date=17 August 2021 }}</ref><ref>{{#invoke:Cite web| |title=A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters |url=https://clinicaltrials.gov/ct2/show/NCT05137236 |website=[[ClinicalTrials.gov]] |date=30 November 2021 |id=NCT05137236 |access-date=30 November 2021 }}</ref>
'''mRNA-1283''' is a [[COVID-19 vaccine]] candidate developed by [[Moderna]].<ref>{{#invoke:Cite web||title=A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04813796 |website=[[ClinicalTrials.gov]] |date=24 March 2021 |id=NCT04813796 |access-date=17 August 2021 }}</ref><ref>{{#invoke:Cite web||title=A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters |url=https://clinicaltrials.gov/ct2/show/NCT05137236 |website=[[ClinicalTrials.gov]] |date=30 November 2021 |id=NCT05137236 |access-date=30 November 2021 }}</ref>

Compared to prior mRNA vaccines, this candidate has a storage temperature of 2-5 °C, compatible with [[vaccine storage]] in a standard refrigerator, rather than low temperature freezers.<ref>{{cite web |title=Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine | url=https://news.modernatx.com/news/news-details/2024/Moderna-Achieves-Positive-Interim-Results-from-Phase-3-Trial-of-Next-Generation-COVID-19-Vaccine/default.aspx|website=news.modernatx.com|access-date=30 May 2024}}</ref> Additionally, the vaccine will be packaged in prefilled syringes, reducing burden on healthcare workers and potentially increasing access.<ref>{{cite web |title=Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine | url=https://news.modernatx.com/news/news-details/2024/Moderna-Achieves-Positive-Interim-Results-from-Phase-3-Trial-of-Next-Generation-COVID-19-Vaccine/default.aspx|website=news.modernatx.com|access-date=30 May 2024}}</ref>

== Clinical Trial ==

In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety.<ref name="pmid37074202">{{cite journal | vauthors = Yassini P, Hutchens M, Paila YD, Schoch L, Aunins A, Siangphoe U, Paris R | title = Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults | journal = Human Vaccines & Immunotherapeutics | volume = 19 | issue = 1 | pages = 2190690 | date = December 2023 | pmid = 37074202 | pmc = 10128428 | doi = 10.1080/21645515.2023.2190690 }}</ref> As of May 2024, the vaccine candidate is in Phase 3 clinical trials, with an estimated completion date of late August 2024.<ref>{{cite web |title=A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE) |url=https://www.clinicaltrials.gov/study/NCT05815498 |website=ClinicalTrials.org |access-date=30 May 2024}}</ref> Preliminary results from this trial indicated the vaccine produced a strong immune response, especially in patients over 65, who are at greater risk for severe outcomes from COVID-19.<ref>{{cite web |title=Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine | url=https://news.modernatx.com/news/news-details/2024/Moderna-Achieves-Positive-Interim-Results-from-Phase-3-Trial-of-Next-Generation-COVID-19-Vaccine/default.aspx|website=news.modernatx.com|access-date=30 May 2024}}</ref>


== References ==
== References ==
Line 53: Line 61:
{{Portal bar | Medicine | Viruses | COVID-19}}
{{Portal bar | Medicine | Viruses | COVID-19}}


[[Category:Clinical trials]]
[[Category:Clinical trials related to COVID-19]]
[[Category:American COVID-19 vaccines]]
[[Category:American COVID-19 vaccines]]
[[Category:RNA vaccines]]
[[Category:RNA vaccines]]

Latest revision as of 20:39, 30 May 2024

mRNA-1283
Vaccine description
TargetSARS-CoV-2
Vaccine typemRNA
Clinical data
Trade namesSpikevax[1]
Routes of
administration		Intramuscular
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Long COVID
Society
Politics
virus icon COVID-19 portal

mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.[2][3]

Compared to prior mRNA vaccines, this candidate has a storage temperature of 2-5 °C, compatible with vaccine storage in a standard refrigerator, rather than low temperature freezers.[4] Additionally, the vaccine will be packaged in prefilled syringes, reducing burden on healthcare workers and potentially increasing access.[5]

Clinical Trial

[edit]

In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety.[6] As of May 2024, the vaccine candidate is in Phase 3 clinical trials, with an estimated completion date of late August 2024.[7] Preliminary results from this trial indicated the vaccine produced a strong immune response, especially in patients over 65, who are at greater risk for severe outcomes from COVID-19.[8]

References

[edit]
  1. ^ "Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day". Bloomberg. 9 September 2021. Retrieved 29 April 2022.
  2. ^ "A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19". ClinicalTrials.gov. 24 March 2021. NCT04813796. Retrieved 17 August 2021.
  3. ^ "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters". ClinicalTrials.gov. 30 November 2021. NCT05137236. Retrieved 30 November 2021.
  4. ^ "Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine". news.modernatx.com. Retrieved 30 May 2024.
  5. ^ "Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine". news.modernatx.com. Retrieved 30 May 2024.
  6. ^ Yassini P, Hutchens M, Paila YD, Schoch L, Aunins A, Siangphoe U, Paris R (December 2023). "Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults". Human Vaccines & Immunotherapeutics. 19 (1): 2190690. doi:10.1080/21645515.2023.2190690. PMC 10128428. PMID 37074202.
  7. ^ "A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)". ClinicalTrials.org. Retrieved 30 May 2024.
  8. ^ "Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine". news.modernatx.com. Retrieved 30 May 2024.
Scholia has a profile for mRNA-1283 (Q110263526).


Stub icon

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=MRNA-1283&oldid=1226467700"